Table 5.
Phenotype | Population and Gene |
SNP-Smoking Interactionc |
Chr | Base Pair Position |
Minor Allele |
MAF | Interaction Effectd |
P Value | Genetic Modele |
---|---|---|---|---|---|---|---|---|---|
FEV1 | African Americans | ||||||||
GLRX2 | rs34552619 × smoking status | 1 | 191331738 | C | 0.08 | −32.4 ± 8.8 | 2.74 × 10−4 | Dominant | |
IDH1 | rs1437410 × smoking pack-years | 2 | 208825562 | C | 0.22 | −1.2 ± 0.4 | 6.27 × 10−4 | Recessive | |
European Americans | |||||||||
SOD3 | rs1007991 × smoking status | 4 | 24409783 | C | 0.34 | 17.9 ± 5.7 | 0.002 | Additive | |
GSTZ1 | rs2111699 × smoking pack-years | 14 | 76858350 | G | 0.32 | −0.4 ± 0.1 | 9.55 × 10−4 | Recessive | |
FEV1/FVC | African Americans | ||||||||
mGST3b | rs7554034 × smoking status | 1 | 163877088 | A | 0.46 | 0.56 ± 0.21 | 0.007 | Recessive | |
IDH3Bb | rs6115381 × smoking status | 20 | 2590376 | G | 0.37 | −0.82 ± 0.23 | 4.60 × 10−4 | Recessive | |
SOD1 | rs2070424 × smoking status | 21 | 31961191 | G | 0.19 | 0.68 ± 0.19 | 3.62 × 10−4 | Dominant | |
G6PD | rs2472394 × smoking pack-years | 23 | 153424545 | A | 0.13 | −0.012 ± 0.003 | 7.75 × 10−4 | Dominant | |
European Americans | |||||||||
mGST3 | rs2297765 × smoking status | 1 | 163888831 | T | 0.44 | 0.45 ± 0.12 | 1.13 × 10−4 | Additive | |
SOD3b | rs2284659 × smoking status | 4 | 24403895 | T | 0.37 | 0.64 ± 0.22 | 0.004 | Recessive | |
IDH3B | rs6115381 × smoking pack-years | 20 | 2590376 | G | 0.07 | −0.008 ± 0.002 | 3.82 × 10−4 | Additive | |
IDH3B | rs6107100 × smoking pack-years | 20 | 2592685 | A | 0.07 | −0.008 ± 0.002 | 3.68 × 10−4 | Additive | |
IDH3B | rs2073192 × smoking pack-years | 20 | 2592996 | A | 0.07 | −0.008 ± 0.002 | 2.10 × 10−4 | Additive |
Abbreviations: FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SNP, single nucleotide polymorphism; Chr, chromosome; MAF, minor allele frequency; GLRX2, glutaredoxin 2; IDH1, isocitrate dehydrogenase 1; SOD3, superoxide dismutase 3; GSTZ1, glutathione S-transferase Z1; mGST3, microsomal glutathione S-transferase 3; IDH3B, isocitrate dehydrogenase 3B; SOD1, superoxide dismutase 1; G6PD, glucose-6-phosphate dehydrogenase.
Data shown are for the most statistically significant gene-by-smoking interactions for each phenotype and race/ethnicity analysis. Statistically significant interactions satisfying the Bonferroni-adjusted threshold (African Americans: P < 2.3 × 10−4; European Americans: P < 3.0 × 10−4) are bolded.
These nominally significant (P < 0.01) interactions were selectively presented since they represent gene-level replications of most statistically significant interactions in another phenotype and race/ethnicity analysis.
Smoking status was defined as a two-level categorical variable: smokers vs. non-smokers (reference group) during follow-up; smoking pack-years was modeled as a continuous variable.
Beta coefficient and standard error for the SNP × smoking × time product term in the corresponding mixed effects model; ml per year for the effect on rate of change in FEV1 and % per year for the effect on rate of change in FEV1/FVC.
Genetic model is defined in reference to the minor allele for each SNP.